Dr. Perales on Ongoing Studies With CAR T Cells in DLBCL

Video

In Partnership With:

Miguel-Angel Perales, MD, discusses replacing autologous stem cell transplant with CAR T-cell therapy in diffuse large B-cell lymphoma.

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses replacing autologous stem cell transplant (ASCT) with CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).

CAR T-cell therapy is approved for patients who have failed on ASCT. Given its efficacy in this setting, investigators have launched 3 large, phase III trials to compare its efficacy with ASCT, says Perales.

In the phase II ZUMA-7 trial, patients in first relapse will be randomized to axicabtagene ciloleucel (axi-cel; Yescarta) or second-line salvage therapy, followed by high-dose therapy and ASCT. The trial recently completed accrual, states Perales.

In two similarly designed studies, patients will receive salvage chemotherapy followed by either CAR T cell-therapy or ASCT, explains Perales. Pending the results of the trials, a cost-effectiveness analysis will need to be done as CAR T-cell therapy is relatively expensive.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,